| Title: |
Densidad ósea en pacientes con trastorno de déficit de atención e hiperactividad en tratamiento con metilfenidato. (Spanish) |
| Alternate Title: |
Bone density in patients with ADHD under methylphenidate treatment. (English) |
| Authors: |
García-Galicia, Arturo; Magallón-Ramírez, Daniel; Muñoz-Padrón, Benjamín; Palacios-Figueroa, Deyaneira; Rodríguez-Palacios, Carlos Leonel; Montiel-Jarquín, Álvaro José; Loria-Castellanos, Jorge; Bertado-Ramírez, Nancy Rosalía |
| Source: |
Revista Mexicana de Pediatria; ene/feb2025, Vol. 92 Issue 1, p12-15, 4p |
| Subject Terms: |
DUAL-energy X-ray absorptiometry; STATISTICAL significance; BONE density; CHILD patients; MANN Whitney U Test |
| Abstract (English): |
Introduction: methylphenidate (MPH) is the most used drug for the treatment of pediatric patients with attention-deficit/hyperactivity disorder (ADHD), but its use has been linked to loss of bone mineral density (BMD). Objective: to compare BMD in pediatric patients with ADHD with and without MPH treatment. Material and methods: an observational, cross-sectional, comparative study conducted between June and August 2021 in a tertiary care hospital. BMD was assessed using DEXA (dual-energy X-ray absorptiometry). Statistical analysis included: Mann-Whitney U test, Fisher's exact test, and Spearman's rho test. Results: thirty-two patients were included, 18 males (56.3%), aged 6 to 16 years. Of the total, 15 were receiving MPH and 17 were not. No differences were found in BMD z-scores between the two groups (p = 0.55), nor in the proportion of low BMD (23.5 vs 20%, p = 0.80). Correlation between the duration of MPH treatment and the BMD z-score was not statistically significant (Rho = -0.05, p = 0.77). Conclusions: in this study, no relationship was demonstrated between the use and duration of MPH treatment and BMD in pediatric patients with ADHD. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): |
Introducción: el metilfenidato (MPH) es el fármaco más utilizado para el tratamiento de pacientes pediátricos con el trastorno por déficit de atención/hiperactividad (TDAH), pero su uso se ha relacionado con la pérdida de densidad mineral ósea (DMO). Objetivo: comparar la DMO en pacientes pediátricos con TDAH con y sin tratamiento de MPH. Material y métodos: estudio observacional, transversal y comparativo, realizado entre junio-agosto del 2021 en un hospital de tercer nivel de atención. La evaluación de la DMO fue con DEXA (dual-energy X-ray absorptiometry). Análisis estadístico: U de Mann-Whitney, prueba exacta de Fisher y rho-Spearman. Resultados: se incluyeron 32 pacientes, 18 varones (56.3%), y con edades de 6 a 16 años. Del total, 15 recibían MPH y 17 no lo recibían. No se encontró diferencia entre los z-scores de la DMO entre los dos grupos (p = 0.55), ni tampoco en la proporción de DMO baja (23.5 vs 20%, p = 0.80). La correlación entre la duración del tratamiento con MPH y el z-score de DMO no fue significativa (Rho = -0.05, p = 0.77). Conclusiones: en este estudio no se demostró relación entre el uso y duración del tratamiento con MPH y la DMO en pacientes pediátricos con TDAH. [ABSTRACT FROM AUTHOR] |
| : |
Copyright of Revista Mexicana de Pediatria is the property of Sociedad Mexicana de Pediatria and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |